News & Insights



Biogen shares jump about 4%

In December, Biogen's drug, Spinraza, was approved to treat a rare infant disease. In the first quarter of 2017, the drug has generated more revenue than expected, raising the company's stock about 4%. Sprinraza is the first drug approved to treat spinal muscular atrophy, a leading genetic cause of death in infants.

Click here to view the entire article.




BACK TO NEWS & INSIGHTS